Refractory shock, cardiogenic shock, denosumab, severe hypocalcaemia
Denosumab is one of the most commonly used antiresorptive drugs for osteoporosis treatment and the prevention of skeletal-related events in cancer patients. The purpose of this case report is to highlight potentially life-threatening severe hypocalcaemia as a side effect of denosumab complicated by refractory shock that failed to respond to medical management including intravenous calcium, vasopressors and inotropes in an elderly man with a history of prostatic cancer.
HTML downloads: 46
PDF downloads: 289
Issue: 2022: Vol 9 No 12 (view)